Myofascial pain syndrome in a patient with ankylosing spondylitis: experience with tolperisone


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Myofascial pain syndrome (MPS) is the most common pathology in the structure of musculoskeletal pain and accounts for 85-90%. The development of MPS is associated with overstrain and microtraumatization of the muscles, followed by the development of the inflammatory process, the release of excess acetylcholine, which promotes muscle contraction. In addition, hyperplasia of connective tissue fibers occurs, the number of nociceptors in muscle fascia increases, local blood flow is disturbed, which ultimately leads to ischemia of muscle tissue areas, increased muscle tone, shortening of muscle fibers, and pain syndrome. Description of the clinical case. The article presents a clinical case illustrating the effectiveness of an integrated approach in the treatment of a patient with MPS. The clinical manifestations of MPS, approaches to diagnosis and methods of treatment are discussed. Conclusion. The possibilities of muscle relaxants (tolperisone) in correcting muscle spasm and reducing pain in myofascial syndrome have been demonstrated.

Full Text

Restricted Access

About the authors

A. A Klimenko

the Pirogov Russian National Research Medical University

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine Moscow, Russia

Natalya A. Demidova

the Pirogov Russian National Research Medical University

Email: ndemidova03@gmail.com
Cand. Sci. (Med.), Associate Professor at the Department of Faculty Therapy n.a. acad. A.I. Nesterov, Faculty of General Medicine Moscow, Russia

D. Yu Andriyashkina

the Pirogov Russian National Research Medical University

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine Moscow, Russia

A. A Kondrashov

the Pirogov Russian National Research Medical University

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine Moscow, Russia

D. V Somov

the Pirogov Russian National Research Medical University

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine Moscow, Russia

A. V Novikova

the Pirogov Russian National Research Medical University

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine Moscow, Russia

References

  1. Gerwin R.D. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep. 2001;5(5):412-20. doi: 10.1007/s11916-001-0052-8.
  2. Fricton J. Myofascial Pain: Mechanisms to Management. Oral Maxillofac Surg Clin North Am. 2016;28(3):289-311. doi: 10.1016/j.coms.2016.03.010.
  3. Xie P, Qin B., Song G. et al. Microstructural Abnormalities Were Found in Brain Gray Matter from Patients with Chronic Myofascial Pain. Front Neuroanat. 2016;10:122. Doi: 10.3389/ fnana.2016.00122.
  4. Bourgaize S., Newton G., Kumbhare D, Srbely J. A comparison of the clinical manifestation and pathophysiology of myofascial pain syndrome and fibromyalgia: implications for differential diagnosis and management. J Can Chiropr Assoc. 2018;62(1):26-41.
  5. Bordoni B., Sugumar K., Varacallo M. Myofascial Pain. 2022 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 30570965
  6. Simons D.G. Clinical and Etiological Update of Myofascial Pain from Trigger Points. J Musculoskeletal Pain. 1996;4:93-122. doi: 10.1300/J094v04n01_07.
  7. Fernandez-de-Las-Penas C., Dommerholt J.International Consensus on Diagnostic Criteria and Clinical Considerations of Myofascial Trigger Points: A Delphi Study. Pain Med. 2018;19(1):142-50. doi: 10.1093/pm/pnx207.
  8. Giamberardino M.A., Affaitati G., Fabrizio A., Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;25(2):185-98. Doi: 10.1016/j. berh.2011.01.002.9.
  9. Quintner J.L., Bove G.M., Cohen M.L. A critical evaluation of the trigger point phenomenon. Rheumatology (Oxford). 2015;54(3):392-99. doi: 10.1093/rheumatology/keu471.
  10. Shah J.P, Thaker N., Heimur J., et al. Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective. PM R. 2015;7(7):746-61. doi: 10.1016/j.pmrj.2015.01.024.
  11. Mazza D.F, Boutin R.D., Chaudhari A.J. Assessment of Myofascial Trigger Points via Imaging: A Systematic Review. Am J Phys Med Rehabil. 2021;100(10):1003-14. doi: 10.1097/PHM.0000000000001789.
  12. Бадокин В.В. Симптоматическая терапия анкилозирующего спондилита. Современная ревматология 2012;(1):69-74.
  13. Hernandez J.V.L., Calvo-Lobo C., Zugasti A.M. et al. Effectiveness of Dry Needling with Percutaneous Electrical Nerve Stimulation of High Frequency Versus Low Frequency in Patients with Myofascial Neck Pain. Pain Physician. 2021;24(2):135-43.
  14. Akpinar F.M., Sindel D., Ketenci A. Investigation of Effectiveness of Two Different Kinesiotaping Techniques in Myofascial Pain Syndrome: An Open-Label Randomized Clinical Trial. Pain Physician. 2021;24(6):E721-31.
  15. Лалаян Т.В., Андреев В.В., Баранцевич Е.Р. Миофасциальный синдром. Клинические проявления, патогенез, диагностика, лечение: учебное пособие. СПб.: РИЦ ПСПбГМУ, 2016. 75 с.
  16. Mazza D.F., Boutin R.D., Chaudhari A.J. Assessment of Myofascial Trigger Points via Imaging: A Systematic Review. Am J Phys Med Rehabil. 2021;100(10):1003-14. doi: 10.1097/PHM.0000000000001789.
  17. Fredy D.M., Harpin D., Mihardja H. The role of acupuncture for myofascial pain syndrome (MPS) in interventional pain management. J Complement Integr Med. 2022;19(2):213-17. Doi: 10.1515/ jcim-2021-0525.
  18. Borg-Stein J., Iaccarino M.A. Myofascial pain syndrome treatments. Phys Med Rehabil Clin N Am. 2014;25(2):357-74. Doi: 10.1016/j. pmr.2014.01.012.
  19. Tough E.A., White A.R., Cummings T.M. et al. Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. Eur J Pain. 2009;13(1):3-10. doi: 10.1016/j.ejpain.2008.02.006.
  20. Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med Chem J. 2014;8:17-22 doi: 10.2174/1874104501408010017.
  21. Frydrych V., Oderda G. Skeletal muscle relaxants drug class review 12:20.04 centrally acting skeletal muscle relaxants. University Utah College Pharm.12(20),1-40.
  22. Caron J., Kaye R., Wessel T., et al. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine. J Clin Pharm Ther. 2020;45(4):774-82. doi: 10.1111/jcpt.13165.
  23. Барулин А.Е., Курушина О.В., Калинченко Б.М. Эффективность применения миорелак-сантов при нижнем перекрестном синдроме. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(9):38-43.
  24. Lakatos P.P., Karadi D.A., Galambos A.R., et al. The Acute Antiallodynic Effect of Tolperisone in Rat Neuropathic Pain and Evaluation of Its Mechanism of Action.Int J Mol Sci. 2022;23(17):9564. doi: 10.3390/ijms23179564

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies